AccessDX Genomic Diagnostics

A New Era of Patient-Specific Medicine

It is well recognized that different patients respond in different ways to the same medication. The need for patient-specific medicine is clear. 

AccessDX’s integrated genomic solution — which includes the unique combination of pharmacogenomics testing (PGx) and therapeutic drug monitoring — dramatically improves clinical judgment and helps physicians form a more accurate, comprehensive and effective treatment regimen for their patients.

Pharmacogenomics Testing

Pharmacogenomics is the study of how genes affect a person’s response to drugs.

AccessDX's PGx evaluates the patient’s metabolic profile, the potential drug/gene and drug/drug interactions. This test establishes a clear understanding of the patient’s potential drug/gene and drug/drug interaction. Starting with a buccal swab, AccessDX conducts PGx to analyze germline variants that may affect how a patient responds to certain drugs. AccessDX identifies patient-specific metabolism for CYP2D6, CYP2C9, CYP2C19, CYP3A4/3A5, CYP1A2, VKORC1, DPYD, TPMT, UGT1A1, Factor II, Factor V, MTHFR, SLCO1B1 and TYMS. The report will reveal if a patient is an ultrarapid, extensive, intermediate or poor metabolizer of relevant drugs.

Specialties most affected by drug/gene and drug/drug interactions are cardiology, psychiatry, pain and internal medicine. 

AccessDX identifies the following drug/gene and drug/drug interactions:

  • Potent inhibitors/inducers which may affect the bioavailability of other drugs on profile
  • Major drug/drug interactions: Category D or X
  • Drugs with a narrow therapeutic window
  • Drugs with Black Box warnings
  • Drugs that may increase the risk of serotonin syndrome, seizures, QTc prolongation and anticholinergic effects

Therapeutic Drug Monitoring

Today's prescribers require diagnostic solutions that improve clinical management of patients. AccessDX is a leading diagnostic and medical decision support company dedicated to providing practitioners with medication monitoring. To achieve this, AccessDX uses the latest drug screening technologies that confirms patient compliance with drug regimens, detection of medication duplications (e.g., opiates) and detection of illicit drug use. Used in combination with our pharmacogenomics testing, medication monitoring enables the optimization of drug dosing and the minimization of drug interactions. 

AccessDX Urine Drug Testing (UDT) Medication Monitoring includes:

  • Baseline testing for new patients, patients initiating opioid therapy, patients on long-term, chronic therapy and random drug testing when appropriate and medically necessary
  • Confirmatory testing for positive baseline testing results, revealing
  • abnormalities in drug metabolism and exposing inconsistencies between desired treatment outcomes and current patient response
  • High-complexity testing with high-performance, LC/MS (liquid chromatography/mass spectrometry) technique to ensure the highest level of
  • sensitivity and specificity
  • Highly-accurate, clinically relevant reports delivered through a secure
  • online portal for rapid results and quick treatment decisions 
  • Credentialed staff of technologists and PharmDs in a CLIA-certified, high-complexity lab

We understand the risks—to both prescriber and patient—associated with medications that are not taken as prescribed. By partnering with AccessDX for medication monitoring, prescribers will receive clinical data that ensures improved patient compliance and outcomes, informed support of treatment decisions for proper and effective medication dosing, and lowered rate of prescription drug misuse to increase patient safety and mitigate prescriber liability.